{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:14:37Z","timestamp":1753892077628,"version":"3.41.2"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2024.1490853","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T07:49:26Z","timestamp":1730792966000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Editorial: Towards continued and affordable accessibility of innovative drugs: sustainable development and efficient use of medicines"],"prefix":"10.3389","volume":"15","author":[{"given":"Atse H.","family":"Huisman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saco","family":"de Visser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Ryll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Barjesteh van Waalwijk van Doorn-Khosrovani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e18831","DOI":"10.1200\/jco.2022.40.16_suppl.e18831","article-title":"Novel ways to fund cost-efficiency studies of expensive drugs: efforts to maintain sustainable healthcare expenditure in the Netherlands","volume":"40","author":"Barjesteh van Waalwijk van Doorn-Khosrovani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"104096","DOI":"10.1016\/j.drudis.2024.104096","article-title":"Reliable business case for repurposing of existing medicines requires key changes in government policies","volume":"29","author":"de Visser","year":"2024","journal-title":"Drug Discov. Today"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejca.2022.03.025","article-title":"Advancing academia-driven treatment optimisation in oncology: launch of the EMA cancer medicines Forum","volume":"168","author":"Saesen","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1001\/jamaoncol.2023.4865","article-title":"Cost savings and waste reduction through redispensing unused oral anticancer drugs: the ROAD study","volume":"10","author":"Smale","year":"2023","journal-title":"JAMA Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2340\/1651-226X.2024.34791","article-title":"PCM4EU and PRIME-ROSE: collaboration for implementation of precision cancer medicine in Europe","volume":"63","author":"Task\u00e9n","year":"2024","journal-title":"Acta Oncol. Madr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-019-1600-x","article-title":"The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs","volume":"574","author":"van der Velden","year":"2019","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/annonc\/mdz119","article-title":"Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients","volume":"30","author":"van Waalwijk van Doorn-Khosrovani","year":"2019","journal-title":"Ann. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(21)00707-5","article-title":"Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform","volume":"23","author":"Zeverijn","year":"2022","journal-title":"Lancet Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1490853\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T07:49:28Z","timestamp":1730792968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1490853\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":9,"alternative-id":["10.3389\/fphar.2024.1490853"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1490853","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"article-number":"1490853"}}